DaVita Clinical Research (DCR), a specialty CRO with services spanning the full spectrum of drug and device development, and Prism Clinical Research, a provider of fully integrated clinical research services to pharma/device companies and clinicians, have announced Verified Clinical Trials (VCT) has been selected by both companies as an exclusive provider to further prevent duplicate enrollment in clinical trials.
Simultaneously enrolling in multiple clinical trials, or duplicate enrollment, has become a serious problem in the clinical research world. A growing number of research volunteers attempt to jump from one study to another without waiting for the appropriate amount of time to lapse. This creates dangerous issues for the drug manufacturer, the research site, the data quality, and, most importantly, the volunteer.
“We are pleased to have these two clinical research leaders join our network,” said Dr. Mitchell Efros, CEO of VCT. “Our system will allow both companies to take big steps forward in preventing duplicate enrollment and the risks associated.”
VCT maintains a global clinical trial research subject database registry to counter attempts at duplicate enrollment in clinical trial research. The majority of phase I units and an increasingly large number of late phase sites in North America use Verified Clinical Trials, making VCT by far the largest North American clinical research subject database registry in both early and late phase clinical trials.
“DCR is passionate about ensuring data quality and research subject safety,” said Amy Young, vice president and general manager of DCR. “Partnering with Prism and using the VCT system is the right thing to do for all our stakeholders.”
Experts and leaders in the field of hepato-renal clinical trials, Prism and DCR join a vast network of research sites and pharmaceutical companies in their efforts to prevent duplicate enrollment and other important protocol violations in clinical trials.
”Prism is glad to be participating in this joint effort with our research neighbor, DCR,” said Jeff Cosgrove, president of Prism Research. “We’ve always been proactive in combating dual enrollment, but VCT gives us state-of-the-art technology and processes toward that end.”
Located in close proximity to the Minneapolis and St. Paul metropolitan area, Prism and DCR specialize in early phase clinical research in healthy volunteer trials and many patient-based volunteer trials, including those in hepatic and renal insufficiency populations.
